BRIEF—China cuts pricing on cancer drugs by up to 9%

Following on previous reductions in the price of oncology drugs in China, the Shanghai government cut prices of 20 cancer drugs, effective on September 30.

16 of the drugs are imported, including Celgene's Revlimid (lenalidomide), Novartis' Afinitor (everolimus) and Roche's MabThera (rituximab).

The price cuts range between 1% and 9%.

Revlimid was approved in China in February this year.

Drugs from Johnson & Johnson subsidiary Janssen, GlaxoSmithKline, AstraZeneca and Bayer are also in the list.